% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • fgnoms fgnoms Jan 5, 2006 9:16 AM Flag

    Impax trial


    The Impax/Shire AdderallXR trial is due to commence on 23rd February. This is a huge trial for Shire. If they lose you wouldn't want to be long thats for sure. Its a risky time to be holding Shire. You could make or lose a lot of money depending on the verdict. And then once that trial is over the Barr one will commence so you've got to go through the whole thing again. And then they'll be the appeals. I'm glad I'm out for the time-being.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Guess you are wrong this time. Remember the old say: No guts, NO glory.

    • Nice job. What a waste of time that post was. Shpgy is positioning for long term growth and this stock is headed much higher.!!

      Maybe you can buy it back in the 60's.

      • 1 Reply to donzoab
      • The post about the impax trial doesn't bother me. The fda gave shire exclusivity up until april no matter how the trial goes.

        We expect to file for approval for both our new add products this quarter. 465 is a longer acting version of adderalxr and will be marketed to adults and teens who need a longer lasting product. Our 503 product is a non narcotic that should find a market with younger pts. The new river product is still a stimulant regardless of it's different properties to reduce over dose and abuse. Physicians and psychiatrists will still look for a non narcotic product to use and strattera as everyone knows has some side effect issues. In fact strattera sales declined in a year when add scripts increased 17% overall.


        Pretty darned nice portfolio of products to sell in a $3B market that expects to grow about 8-10% a year.